ClinicalTrialsFinder

Acute Myeloid Leukemia With FLT3/ITD Mutation Clinical Trials in Chapel Hill, North Carolina

1 recruitingChapel Hill, North Carolina

Showing 1–1 of 1 trials

Recruiting
Phase 1

SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation

Recurrent Acute Myeloid LeukemiaRefractory Acute Myeloid LeukemiaAcute Myeloid Leukemia With FLT3/ITD Mutation+2 more
Uma Borate30 enrolled3 locationsNCT06222580